Core Viewpoint - BeiGene, Ltd. is experiencing significant growth in revenue and net profit, indicating strong performance in the biotechnology sector focused on cancer treatment [1][2]. Financial Performance - As of March 31, 2025, BeiGene reported total revenue of $1.117 billion, representing a year-over-year increase of 48.64% [1]. - The net profit attributable to shareholders reached $1.27 million, showing a remarkable growth of 100.51% compared to the previous year [1]. Company Overview - BeiGene is a commercial-stage biotechnology company specializing in the development and commercialization of innovative molecular targeted and immunotherapy drugs for cancer treatment [2]. - The company has a diverse product portfolio, including six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2]. - BeiGene has also secured licensing for five drugs and investigational products, including three drugs already marketed in China under exclusive license from Celgene: ABRAXANE, REVLIMID, and VIDAZA [2]. - Founded in Beijing in 2010, BeiGene went public on the NASDAQ Global Select Market in February 2016 and has built a global team of over 1,300 employees as of July 2018, showcasing its comprehensive capabilities in research, clinical development, manufacturing, and commercialization [2].